|
mrsa |
11 |
|
adenosine synthase a |
7 |
|
inhibitor |
7 |
|
nlrp3 inflammasome |
7 |
|
staphylococcus aureus |
7 |
|
t cell responses |
7 |
|
target |
7 |
|
s. aureus |
6 |
|
saer |
6 |
|
virulence |
6 |
|
adjuvants |
5 |
|
antibiotic tolerance |
5 |
|
persistent infections |
5 |
|
persister |
5 |
|
antimicrobial property |
4 |
|
antivirulence |
4 |
|
bacterial infection |
4 |
|
biocompatibility |
4 |
|
clpp |
4 |
|
multivalent vaccine |
4 |
|
orthopedic implant |
4 |
|
surface modification |
4 |
|
titanium alloy |
4 |
|
virulence factors |
4 |
|
γδ t cell |
4 |
|
abdominal infection |
3 |
|
animal cell |
3 |
|
animal experiment |
3 |
|
animal model |
3 |
|
animal tissue |
3 |
|
anti-virulence |
3 |
|
beta-lactams |
3 |
|
antimicrobial resistance |
2 |
|
biochemical genetics |
2 |
|
lysozyme |
2 |
|
mycobacterium tuberculosis |
2 |
|
ocular microbiome |
2 |
|
oxazolidinone-class antibiotics |
2 |
|
phosphorylated prodrugs |
2 |
|
staphylococcus aureus infections |
2 |
|
staphyloxanthin |
2 |
|
tedizolid phosphate |
2 |
|
4-diphosphocytidyl-2-c-methyl-d-erythritol synthase (cdp-mep synthase, ispd) |
1 |
|
actinomycin |
1 |
|
actinomycin d |
1 |
|
anti-tb compounds |
1 |
|
antituberculosis activity |
1 |
|
bama |
1 |
|
cell wall |
1 |
|
cell wall core |
1 |
|
corynebacterium glutamicum |
1 |
|
d-alanine–d-alanine ligase |
1 |
|
d-cycloserine |
1 |
|
dmb (domiphen bromide) |
1 |
|
dna gyrase |
1 |
|
drug screening model |
1 |
|
drug-resistance |
1 |
|
gram-negative bacteria |
1 |
|
high throughput screening |
1 |
|
isocitrate lyase |
1 |
|
isocitrate lyase inhibitor |
1 |
|
isolation and purification |
1 |
|
mycolic acid |
1 |
|
outer membrane |
1 |
|
pantothenate synthetase |
1 |
|
pharmacophore |
1 |
|
screening system |
1 |
|
tetrahydrothieno[2,3-c]pyridine derivatives |
1 |
